Johnson & Johnson (US)

Dexamethasone reduces infusion-related reactions in patients with EGFR -mutated non-small cell lung cancer treated with intravenous RYBREVANT ® (amivantamab-vmjw)

Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT ® , a three-fold reduction from 67.4 percent historically seen with standard IRR management SAN DIEGO, CA, September 10, 2024 – Johnson &...

RYBREVANT ® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer

New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapyfree RYBREVANT® plus LAZCLUZE™ regimen compared to osimertinib monotherapy as firstline therapy Results from an interim analysis featured in late-breaker oral...

Financial

Innovative Medicine

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

New Brunswick, N.J., September 5 th , 2024 – Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 15 th to review third-quarter results. Joaquin Duato, Chairman and Chief...

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies Filing based on the Phase 3 Vivacity-MG3 program, the first-and-only study...

DePuy Synthes Launches MatrixSTERNUM™ Fixation System for Enhanced Chest Stability Following Cardiac Surgery

Innovative system, now available in the U.S., offers strength, speed and contourability, 1-4, ‡,§,¶,||#, addressing critical patient need in cardiac procedures 3,4 WEST CHESTER, Penn. – August 29, 2024 – Today, DePuy Synthes, The Orthopaedics...

European Commission approves RYBREVANT ® ▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy

Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on an EGFR TKI 1,2,3,4 Amivantamab in combination with...

Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress

Four RYBREVANT ® (amivantamab-vmjw) studies feature compelling new findings in lung and colorectal cancers New TAR-200 data reveal the potential of organ-sparing therapy for the treatment of bladder cancer RARITAN, NJ, August 27, 2024 – Johnson...

Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024

NEW BRUNSWICK, N.J. (August 26, 2024) -- Johnson & Johnson (NYSE: JNJ) today announced that Dr. Peter M. Fasolo will retire from his position as Executive Vice President, Chief Human Resources Officer at the end of this year, following 16 years of...